Skip to main content
LFVN
NASDAQ Life Sciences

LifeVantage Appoints Terrence Moorehead as CEO, Details Substantial Compensation

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Positive
Importance info
9
Price
$4.57
Mkt Cap
$58.518M
52W Low
$3.9
52W High
$15.23
Market data snapshot near publication time

summarizeSummary

LifeVantage Corporation announced the appointment of Terrence O. Moorehead, a seasoned executive with a strong turnaround record, as its new President and CEO, effective August 5, 2026, alongside an interim CEO appointment and a significant compensation package for Mr. Moorehead.


check_boxKey Events

  • New CEO Appointed

    Terrence O. Moorehead, former CEO of Nature's Sunshine Products, Inc. (where he grew revenue 45% and EBITDA 190%), will become President and CEO effective August 5, 2026.

  • Interim Leadership

    Current director Michael Beindorff will serve as Interim CEO from May 1, 2026, until Mr. Moorehead's start date, receiving $45,833 per month.

  • Outgoing CEO Transition

    Steven R. Fife's retirement is effective April 30, 2026, with a transition agreement including advisory services, continued vesting of some equity, and a restriction on selling more than 20,000 shares per trading day.

  • Significant Compensation Package

    New CEO Terrence Moorehead's compensation includes an $850,000 base salary, a guaranteed $425,000 bonus for fiscal year 2027, and $7.5 million in restricted and performance-based stock unit awards.


auto_awesomeAnalysis

This 8-K details a critical leadership transition for LifeVantage, which recently reported a steep revenue decline. The appointment of Terrence O. Moorehead, known for significantly growing revenue and EBITDA at his previous company, signals a strategic move to revitalize the business. While his compensation package, including $7.5 million in equity awards, represents substantial potential dilution, the market may view this as a necessary investment to attract a high-caliber leader capable of driving a turnaround. The interim CEO appointment ensures continuity during the transition period. Investors will be watching for Mr. Moorehead's strategic initiatives and how the company's performance evolves under his leadership.

At the time of this filing, LFVN was trading at $4.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $58.5M. The 52-week trading range was $3.90 to $15.23. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed LFVN - Latest Insights

LFVN
Apr 21, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
LFVN
Apr 16, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
9
LFVN
Apr 02, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
LFVN
Mar 02, 2026, 6:44 PM EST
Filing Type: 4
Importance Score:
7
LFVN
Feb 04, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
9
LFVN
Feb 04, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
9